Quince Therapeutics (QNCX) Restructuring Costs (2024 - 2026)

Quince Therapeutics has reported Restructuring Costs for 3 years, with the latest figure at -$1.3 million in Q2 2026.

• On a quarterly basis, Restructuring Costs fell 290.79% year-over-year to -$1.3 million in Q2 2026; TTM through Jun 2026 was $628000.0, a 78.73% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 21.98% from the prior year.
• Restructuring Costs was -$1.3 million for Q2 2026 at Quince Therapeutics, down from $630000.0 in the prior quarter.
• The five-year high for Restructuring Costs was $970000.0 in Q2 2024, with the low at -$1.3 million in Q2 2026.
• Average Restructuring Costs over 3 years is $505555.6, with a median of $664000.0 recorded in 2025.
• The largest YoY upside for Restructuring Costs was 2.33% in 2026 against a maximum downside of 290.79% in 2026.
• Over 3 years, Restructuring Costs stood at $774000.0 in 2024, then fell by 14.21% to $664000.0 in 2025, then plunged by 296.54% to -$1.3 million in 2026.
• The last three Restructuring Costs figures came in at -$1.3 million (Q2 2026), $630000.0 (Q1 2026), and $664000.0 (Q4 2025), per Business Quant data.